Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ERGO
Entia Biosciences
$0.00
$0.00
$0.00
N/A12.3150 shsN/A
Graphite One Inc. stock logo
GPH
Graphite One
C$0.92
+17.9%
C$0.87
C$0.55
C$1.07
C$93.15M1.0264,096 shs309,097 shs
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
$5.00
-1.2%
$3.49
$1.97
$22.47
$149.65M1.2300,986 shs139,376 shs
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
$1.93
+2.1%
$1.39
$0.77
$2.12
$192.57M2.341.51 million shs4.28 million shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ERGO
Entia Biosciences
0.00%0.00%0.00%0.00%0.00%
Graphite One Inc. stock logo
GPH
Graphite One
+17.95%+16.46%0.00%-7.07%+5.75%
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
-1.19%-2.72%+48.81%+4.82%-77.18%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
+2.12%-0.52%+37.86%+67.83%+37.86%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ERGO
Entia Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Graphite One Inc. stock logo
GPH
Graphite One
N/AN/AN/AN/AN/AN/AN/AN/A
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
3.6952 of 5 stars
4.44.00.00.03.71.70.6
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
0.408 of 5 stars
0.02.00.00.03.50.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ERGO
Entia Biosciences
0.00
N/AN/AN/A
Graphite One Inc. stock logo
GPH
Graphite One
0.00
N/AN/AN/A
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
2.71
Moderate Buy$33.83576.67% Upside
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest GPH, SLS, ERGO, and SLN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2025
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$4.00 ➝ $3.00
5/9/2025
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$45.00 ➝ $25.00
5/9/2025
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $35.00
3/7/2025
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
3/5/2025
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$49.00 ➝ $45.00
3/4/2025
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$67.00 ➝ $25.00
3/4/2025
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$6.00 ➝ $4.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ERGO
Entia Biosciences
N/AN/AN/AN/AN/AN/A
Graphite One Inc. stock logo
GPH
Graphite One
N/AN/AC$0.01 per share94.17C$0.44 per shareN/A
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
$27.70M5.40N/AN/A$0.71 per share7.04
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
$1M192.57N/AN/A($0.25) per share-7.72
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ERGO
Entia Biosciences
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Graphite One Inc. stock logo
GPH
Graphite One
-C$4.90M-C$0.07N/AN/AN/A-10.96%-6.61%N/A
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
-$53.82M-$1.50N/AN/AN/A-342.00%-62.81%-33.89%N/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-$37.34M-$0.38N/AN/AN/AN/A-629.46%-178.65%8/12/2025 (Estimated)

Latest GPH, SLS, ERGO, and SLN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-$0.1067-$0.07+$0.0367-$0.07N/AN/A
5/8/2025Q1 2025
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
-$0.18-$0.60-$0.42-$0.60$3.58 million$0.14 million
3/20/2025Q4 2024
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-$0.1067-$0.08+$0.0267-$0.08N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ERGO
Entia Biosciences
N/AN/AN/AN/AN/A
Graphite One Inc. stock logo
GPH
Graphite One
N/AN/AN/AN/AN/A
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
N/AN/AN/AN/AN/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ERGO
Entia Biosciences
N/AN/AN/A
Graphite One Inc. stock logo
GPH
Graphite One
0.02
1.09
0.33
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
N/A
9.31
9.31
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
N/A
2.26
2.26

Institutional Ownership

CompanyInstitutional Ownership
ERGO
Entia Biosciences
N/A
Graphite One Inc. stock logo
GPH
Graphite One
0.07%
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
98.73%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
17.38%

Insider Ownership

CompanyInsider Ownership
ERGO
Entia Biosciences
28.30%
Graphite One Inc. stock logo
GPH
Graphite One
28.81%
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
2.95%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
1.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
ERGO
Entia Biosciences
6N/AN/ANot Optionable
Graphite One Inc. stock logo
GPH
Graphite One
20101.25 millionN/ANot Optionable
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
10029.93 millionN/ANot Optionable
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
1099.78 million69.54 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Entia Biosciences OTCMKTS:ERGO

Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.

Graphite One stock logo

Graphite One CVE:GPH

C$0.92 +0.14 (+17.95%)
As of 05/27/2025 03:59 PM Eastern

Graphite One Inc. operates as mineral exploration company in the United States. The company holds interest in the Graphite Creek property that consists of 135 mining claims located on the Seward Peninsula, Alaska. The company was formerly known as Graphite One Resources Inc. and changed its name to Graphite One Inc. in February 2019. Graphite One Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.

Silence Therapeutics stock logo

Silence Therapeutics NASDAQ:SLN

$5.00 -0.06 (-1.19%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$5.02 +0.02 (+0.40%)
As of 05/27/2025 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

SELLAS Life Sciences Group stock logo

SELLAS Life Sciences Group NASDAQ:SLS

$1.93 +0.04 (+2.12%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$1.94 +0.01 (+0.73%)
As of 05/27/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.